ArticleAndrology2025
Peyronie's disease in the United States: A real-world, 13-year nationwide analysis of demographics, clinical characteristics, and treatment trends.
Article in Andrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The impact of collagenase clostridium histolyticum (CCH) priming on surgical outcomes in Peyronie's disease: a retrospective cohort study.Translational andrology and urology · 2026Article
- From fibrosis to restoration: the multimodal 3 Ts protocol for Peyronie's disease.International journal of impotence research · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundReal-world data on Peyronie's disease remains limited.
objectivesDescribe the demographics, clinical characteristics, and therapeutic management of Peyronie's disease patients in the United States. MATERIALS AND
methodsA retrospective analysis was conducted using the PearlDiver Mariner database (2010-2022). Male adults with Peyronie's disease were identified using the International Classification of Diseases codes. Data included demographics, clinical conditions, and treatments. Analysis was performed using R-based software.
resultsAmong 176,969 patients (mean age 58.9 years), hypertension (72.9%), diabetes (40.4%), and obesity (31.1%) were the most common comorbidities. Smoking was prevalent in 41.5%. Dupuytren's contracture affected 3.1%, penile trauma 0.2%, erectile dysfunction 28.2%, and depression 19%. Most patients were from the southern US (42.9%). Social determinants of health were noted in 30.9%. Treatment was received by only 13.2%. Intraplaque injections were the most frequent therapy (7.2%) and showed an increasing trend (p = 0.014). Surgical interventions (8.1%) included plication (35.1%), grafting (13%), prosthesis implantation (36.2%), and multiple techniques (15.7%). Grafting was linked to higher de novo erectile dysfunction risk. DISCUSSION: Hypertension, diabetes, and smoking are frequent among Peyronie's disease patients. Erectile dysfunction and depression are common within a year of diagnosis. Despite multiple treatment options, only 15% of patients receive therapy. Injections are increasingly preferred, while surgery remains underutilized. Inflatable prostheses are the favored option for prosthetic management.
conclusionPeyronie's disease patients often have significant comorbidities. Treatment rates are low, with injections as the most used therapy. Surgical interventions are less common, with stable trends over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.